Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 97Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 10Recurrence 8Leukemia 8Neoplasm, Residual 6Hematologic Neoplasms 6Myeloproliferative Disorders 5Lymphoma, T-Cell, Peripheral 5Leukemia, Biphenotypic, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Monocytic, Acute 3Anemia, Refractory, with Excess of Blasts 3Myeloid Malignancy 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2GATA2 Deficiency 2Breast Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Pathologic Complete Response 1

Interventions

glofitamab 2Rituximab 2Cyclophosphamide 2zanubrutinib 1pirtobrutinib 1pegfilgrastim 1obinutuzumab 1mirabegron 1Vincristine 1Specimen Handling 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Lenalidomide 1Doxorubicin 1Dexrazoxane 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Dendritic Cell Sarcoma, Interdigitating × Azacitidine × Clear all
NCT06158399 2025-02-19

AZA Combined With RCHOP in P53-mutated DLBCL.

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
52 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡